Jan Rosing Selected Research

Protein S

1/2017	The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
9/2010	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.
4/2010	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families.
1/2007	Rapid activation of haemostasis after hormonal emergency contraception.
1/2007	The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus.
9/2006	Venous thrombosis and oral contraceptives: current status.
2/2006	Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
5/2005	Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
12/2004	Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance.
6/2004	The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APC-cofactor and APC-independent anticoagulant activities.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan Rosing Research Topics

Disease

29	Activated Protein C Resistance (APC Resistance) 02/2016 - 03/2002
21	Venous Thrombosis (Deep-Vein Thrombosis) 08/2014 - 07/2002
15	Thrombosis (Thrombus) 07/2013 - 05/2004
8	Venous Thromboembolism 05/2017 - 07/2002
5	Hemorrhage 01/2020 - 12/2003
5	Protein S Deficiency (Deficiency, Protein S) 09/2010 - 07/2002
3	Thrombophilia 01/2021 - 01/2003
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 09/2004
2	Hemophilia A (Haemophilia) 01/2014 - 09/2004
2	Inflammation (Inflammations) 07/2013 - 02/2006
2	Factor V Deficiency 01/2010 - 11/2008
2	Neoplasms (Cancer) 02/2006 - 01/2003
1	Coronary Disease (Coronary Heart Disease) 02/2016
1	Obesity 07/2013
1	Ischemic Stroke 04/2012
1	Stroke (Strokes) 04/2012
1	Lacunar Stroke 04/2012
1	Essential Thrombocythemia 11/2008
1	Polycythemia Vera 11/2008
1	Disease Susceptibility (Diathesis) 11/2008
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2007
1	Atherosclerosis 02/2006
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 04/2005
1	Neoplasm Metastasis (Metastasis) 01/2003
1	Breast Neoplasms (Breast Cancer) 01/2003
1	Protein C Deficiency 07/2002

Drug/Important Bio-Agent (IBA)

23	Protein CIBA 01/2017 - 07/2002
23	Thrombin FDA Link 01/2017 - 03/2002
13	Protein SIBA 01/2017 - 01/2003
9	factor V LeidenIBA 01/2020 - 07/2002
9	Oral ContraceptivesIBA 05/2017 - 07/2002
9	Prothrombin (Factor II)IBA 07/2013 - 07/2002
8	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2017 - 02/2006
8	Factor V (Coagulation Factor V)IBA 08/2014 - 09/2002
7	Estrogens (Estrogen)FDA Link 02/2016 - 06/2003
5	Hemostatics (Antihemorrhagics)IBA 01/2017 - 06/2003
5	Progestins (Progestagens)IBA 02/2016 - 02/2005
5	Thromboplastin (Tissue Factor)IBA 02/2016 - 01/2003
5	Levonorgestrel (Plan B)FDA LinkGeneric 07/2010 - 02/2004
5	AnticoagulantsIBA 02/2006 - 05/2004
4	Hormones (Hormone)IBA 01/2017 - 07/2006
4	Contraceptive Agents (Contraceptives)IBA 04/2013 - 02/2008
3	AntithrombinsIBA 01/2017 - 07/2002
3	Fibrinogen (Factor I)FDA Link 08/2014 - 01/2007
3	Sex Hormone-Binding GlobulinIBA 04/2009 - 02/2005
3	Desogestrel FDA LinkGeneric 09/2006 - 02/2004
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 04/2009
2	AntigensIBA 01/2017 - 12/2002
2	C-Reactive ProteinIBA 07/2013 - 01/2007
2	Combined Oral ContraceptivesIBA 04/2013 - 04/2009
2	PhosphatidylserinesIBA 07/2011 - 11/2007
2	GestodeneIBA 09/2006 - 02/2005
2	Proteins (Proteins, Gene)FDA Link 02/2006 - 06/2003
2	AntibodiesIBA 04/2005 - 09/2004
1	A-factor (Streptomyces)IBA 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2017
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2017
1	Warfarin (Coumadin)FDA LinkGeneric 01/2017
1	Peptides (Polypeptides)IBA 08/2014
1	Plasminogen InactivatorsIBA 07/2013
1	Biological ProductsIBA 04/2013
1	platelet factor VIBA 01/2010
1	CopperIBA 04/2009
1	Progesterone FDA LinkGeneric 12/2007
1	Estradiol (Delestrogen)FDA LinkGeneric 12/2007
1	IntegrinsIBA 11/2007
1	FibrinIBA 11/2007
1	CollagenIBA 11/2007
1	estropipate (Ogen)FDA LinkGeneric 11/2007
1	prothrombin fragment 1IBA 01/2007
1	ApolipoproteinsIBA 01/2007
1	Apolipoproteins B (ApoB)IBA 01/2007
1	SteroidsIBA 01/2007
1	Norethindrone Acetate (Norlutate)FDA LinkGeneric 07/2006
1	Factor Xa (Coagulation Factor Xa)IBA 05/2005
1	Immunoglobulin G (IgG)IBA 04/2005
1	Phospholipids (Phosphatides)FDA LinkGeneric 04/2005
1	Raloxifene Hydrochloride (Evista)FDA Link 10/2004
1	HomocysteineIBA 10/2004
1	Selective Estrogen Receptor Modulators (SERM)IBA 10/2004
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 09/2004
1	Fish OilsIBA 09/2004
1	protein S HeerlenIBA 06/2004
1	factor V CambridgeIBA 02/2004
1	Factor XI (Plasma Thromboplastin Antecedent)IBA 12/2002
1	Factor VIII (Coagulation Factor VIII)IBA 12/2002
1	Protein Isoforms (Isoforms)IBA 09/2002

Therapy/Procedure

6	Therapeutics 01/2017 - 06/2003
3	Hormone Replacement Therapy (Therapy, Hormone Replacement) 06/2003 - 07/2002
2	Intrauterine Devices (Intrauterine Device) 07/2010 - 04/2009
1	Lasers (Laser) 07/2011
1	Female Contraceptive Devices (Vaginal Ring) 07/2010
1	Oral Administration 07/2006
1	Intranasal Administration 07/2006
1	Estrogen Replacement Therapy 06/2003